Ionis Pharmaceuticals, Inc.
NASDAQ:IONSBiotechnology
+$1.22 today
- Market cap
- $4.56B
- Beta
- 0.37
- P/E (TTM)
- -37.5
- EPS (TTM)
- -$1.98
Volume 3.23M
Average 1.83M
IONS Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Ionis Pharmaceuticals, Inc.NASDAQ: IONS
Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026
Accounts receivables declines year over year
Q3 FY2026 accounts receivables of $29.5M (cash outflow) fell 25.5% year over year, behind the -14.2% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -10.4% a year.
Context
- Accounts receivables amounted to 2.8% of revenue in FY2025, up 2.0 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -25.5% toward the trailing-twelve-month pace of -14.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 26.13M USD
- Year-over-year change
- +367.4%
- 4-year CAGR
- +50.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.13M | +367.4% |
| FY2024 | 2024-12-31 | 5.59M | +107.8% |
| FY2023 | 2023-12-31 | (72.06M) | -298.2% |
| FY2022 | 2022-12-31 | 36.36M | +620.0% |
| FY2021 | 2021-12-31 | 5.05M | — |
Accounts Receivables vs competitors
How IONS compares with its peers on the latest reported figures
- IONS's LTM Sep 2026 accounts receivables of $63.73M is the 6th largest of the 9 companies compared; the peer median is $33.22M.
- Its year-over-year change of -14.2% is the 6th highest of 9, against a peer median of +90.7%.
- Accounts receivables amounts to 6.6% of revenue for IONS, versus a peer median of 5.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $60.56B | +173755.7% | +40.6% | 5.9% | |
| LTM Jun 2026 | $357.64M | +48.4% | +99.1% | 7.4% | |
| LTM Mar 2026 | $264.55M | +194.3% | — | 12.1% | |
| LTM Jun 2026 | $208.4M | +578.8% | — | 2.1% | |
| LTM Jun 2026 | $177.62M | +133.1% | — | 24.9% | |
| LTM Sep 2026 | $63.73M | -14.2% | -10.4% | 6.6% | |
| LTM Jun 2026 | $44.38M | -720.6% | -40.6% | 4.4% | |
| LTM Mar 2026 | $22.06M | -1708.0% | +37.0% | 3.3% | |
| LTM Mar 2026 | $1.37M | -94.7% | -18.2% | 2.1% | |
| Peer median (excluding IONS) | $33.22M | +90.7% | +37.0% | 5.1% | |
Competitors are the stored peer set for IONS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (28.6M) | (269.72M) | (366.29M) | (453.9M) | (381.39M) |
| Depreciation & Amortization | 19.56M | 22.11M | 22.5M | 21.99M | 22.69M |
| Deferred Income Tax | 25.31M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 120.68M | 100.26M | 105.81M | 130.2M | 133.87M |
| Change in Working Capital | (113.82M) | 7.57M | (77.26M) | (209.39M) | (51.22M) |
| Accounts Receivables | 5.05M | 36.36M | (72.06M) | 5.59M | 26.13M |
| Inventory | (2.84M) | 2.77M | (6.39M) | (5.07M) | (13.67M) |
| Accounts Payables | (6M) | 1.09M | 8.12M | 15.99M | (15.36M) |
| Other Working Capital | (110.03M) | (32.65M) | (6.93M) | (225.9M) | (48.31M) |
| Other Non-Cash Items | 7.67M | (134.59M) | 7.73M | 10.15M | 7.45M |
| Operating Cash Flow | 30.8M | (274.37M) | (307.51M) | (500.95M) | (268.58M) |
| Capital Expenditures | (17.9M) | (20.1M) | (28.01M) | (45.28M) | (51.44M) |
| Acquisitions (Net) | 5.95M | 254.08M | 22K | 0 | 0 |
| Purchases of Investments | (1.13B) | (1.49B) | (1.77B) | (1.85B) | (1.92B) |
| Sales of Investments | 1.34B | 989.15M | 1.58B | 1.77B | 1.7B |
| Other Investing Activities | (5.95M) | 0 | (4.21M) | (5.06M) | (5.64M) |
| Investing Cash Flow | 194.91M | (262.64M) | (214.13M) | (134.03M) | (277.78M) |
| Debt Repayment | 313.57M | (50.69M) | 86.9M | (44.67M) | 483.24M |
| Common Stock Issued | 85.71M | 6.37M | 49.44M | 522.73M | 192.6M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (153.35M) | (10.98M) | 507.74M | 0 | 0 |
| Financing Cash Flow | 245.93M | (55.3M) | 644.08M | 478.06M | 675.84M |
| Effect of Forex Changes | (111K) | (418K) | 352K | (273K) | 702K |
| Net Change in Cash | 471.53M | (592.72M) | 122.79M | (157.19M) | 130.18M |
| Free Cash Flow | 12.9M | (294.47M) | (335.52M) | (546.23M) | (320.03M) |
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
Intrinsic Alpha fair value
Locked
Current Price
$27.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.